<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stone, John H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-Term Results of the RAVE Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results of the 18-month follow-up from the Rituximab in ANCA-Associated Vasculitis trial [RAVE; ISRCTN28528813; Stone JH et al. N Engl J Med 2010], which found that one course of treatment with rituximab was noninferior to standard course of therapy (cyclophosphamide followed by azathioprine) for remission-induction of severe antineutrophil cytoplasmic antibody-associated vasculitis.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>